Sign In
Buy MLTX
$18.27
+0.400 (+2.24%)
At Close: Jun 03, 2026
SAN FRANCISCO , Nov. 26, 2025 /PRNewswire/ -- MoonLake Immunotherapeutics (NASDAQ: MLTX), a clinical-stage biotechnology company, has been hit with a securities fraud class action lawsuit after its sh
New York, New York--(Newsfile Corp. - November 26, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: M
MLTX Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO , Nov. 25, 2025 /PRNewswire/ -- MoonLake Immunotherapeutics (NASDAQ: MLTX), a clinical-stage biotechnology company, has be
NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit.
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Company: MoonLake Immunotherapeutics (MLTX) is a Swiss clinical-stage biotechnology company focused on inflammatory diseases driven by interleukin-17 (IL-1
MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX
09:56am, Tuesday, 25'th Nov 2025
LOS ANGELES, Nov. 25, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against MoonLake Immunotherapeutics (“MoonLake” or “the Company”) (NASDAQ: MLTX) fo
NEW YORK , Nov. 25, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit. CLAS
New York, New York--(Newsfile Corp. - November 24, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) betw
SAN FRANCISCO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- MoonLake Immunotherapeutics (NASDAQ: MLTX), a clinical-stage biotechnology company, has been hit with a securities fraud class action lawsuit after it
NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX).
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm
10:20am, Monday, 24'th Nov 2025
LOS ANGELES, Nov. 24, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MoonLake Immunotherapeutics (“
NEW YORK , Nov. 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX). Shareholders who purchased shares of MLTX during
NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or a
PHILADELPHIA , Nov. 24, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake" or the "
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics
08:36am, Monday, 24'th Nov 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In MoonLake To Contact Him Directly To Discuss Their Options If you purchased or acquire
